findmyKOL

Grazia Aleppo, MD

Enriched profile

Professor of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine; Associate Chief for Clinical Affairs · Northwestern University Feinberg School of Medicine

ORCIDNPI
Region🇺🇸 Chicago, IL · Midwest · United StatesSpecialtyEndocrinology, Diabetes & MetabolismFocusDiabetes Management and Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Grazia Aleppo is Professor of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine; Associate Chief for Clinical Affairs at Northwestern University Feinberg School of Medicine. OpenAlex indexes 289 publications with 25,632 citations (h-index 74); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Grazia Aleppo, MD, is Professor of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine at Northwestern University Feinberg School of Medicine. The public record shows 289 publications with 25,632 citations (h-index 74), centered on Diabetes Management and Research, Diabetes Treatment and Management, Diabetes and associated disorders. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 13 companies.

  • Most recent indexed publication: 2026 · Journal of diabetes science and technology
  • Top research focus: Diabetes Management and Research
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 13 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Type 1 Diabetes6 trialsType 2 Diabetes5 trials

Research focus

OpenAlex concept fingerprint
Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes and associated disordersHyperglycemia and glycemic control in critically ill and hospitalized patientsPancreatic function and diabetes

Drugs & molecules

across trials, industry payments and publications
Kerendiageneric · FinerenoneClinical trialsIndustry payments15PublicationsDEXCOM STELO GLUCOSE BIOSENSORClinical trialsIndustry payments5PublicationsAfrezzageneric · Insulin, regular, humanClinical trialsIndustry payments2Publications

Works with

trial sponsors and companies reporting payments
Insulet CorporationClinical trials2Industry payments19Dexcom, Inc.Clinical trialsIndustry payments74Bayer HealthCare Pharmaceuticals Inc.Clinical trialsIndustry payments15

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
289publications

Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.

25,632citations

Total citations across indexed works.

74h-index

Hirsch index (OpenAlex). i10-index 158.

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials
13companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    72.1%
    Insulin Analog35.8%
    Lantus Solostar30%Humalog Kwikpen U-10013%Novolog Flexpen10%Humalog9%Basaglar Kwikpen U-1009%Tresiba Flextouch U-1007%Fiasp Flextouch4%Novolog4%Humalog Kwikpen U-2003%Insulin Lispro Kwikpen U-1003%Admelog Solostar3%Tresiba Flextouch U-2003%Lantus2%Insulin Lispro2%
    Part D<11 patients
    GLP-1 receptor agonist13.6%
    Ozempic49%Mounjaro34%Trulicity17%
    Part D38 patients
  • Hormonal (systemic)

    16%
    l-Thyroxine14.5%
    Levothyroxine Sodium74%Synthroid26%
    Part D61 patients
    Antihypoglycemic Agent0.8%
    Gvoke Hypopen 2-Pack100%
    Part D11 patients
  • Cardiovascular

    9.6%
    Statin6.5%
    Atorvastatin Calcium63%Rosuvastatin Calcium37%
    Part D30 patients
    ACE inhibitor1%
    Lisinopril100%
    Part D<11 patients
3 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)17.5% facility · 82.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

40 congress contributions (2018–2026) across AACE, ADA, ENDO per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Jane Jeffrie Seley69Raveendhara R. Bannuru67Robert C. Stanton67

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/grazia-aleppo-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/grazia-aleppo-6b764347

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • LinkedIn

    linkedin.com/in/grazia-aleppo-kacmarek-2a75a1241

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
1 more verified account behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/reel/C8pmG0Ot8TK

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com
  • Other

    breakthroughsforphysicians.nm.org/endocrinology-clinical-podcast-expanding-the-role-of-cgm-in-type-2-diabetes-insights-from-grazia-aleppo-md.html

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breakthroughsforphysicians.nm.org
  • Other

    breakthroughsforphysicians.nm.org/endocrinology-research-podcast-grazia-aleppo-md-discusses-inhale-3-trial-and-diabetes-technology-updates.html

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breakthroughsforphysicians.nm.org
5 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Chair

    Endocrine Society Clinical Affairs Core Committee

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pro.aace.com
  • Associate Editor

    Diabetes Technology and Therapeutics

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com
  • Editorial Board member

    BMJ Open Diabetes Research & Care

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com
2 more roles behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.